Subcutaneous and transcutaneous monitoring of murine hindlimb ischemia by in vivo Raman spectroscopy

Literature Information

Publication Date 2019-07-03
DOI 10.1039/C8AN02449A
Impact Factor 4.616
Authors

Rida Al-Rifai, Samar Kheirallah, Nicole Bouland, Gaël Poitevin, Abdelilah Beljebbar


View Original

Abstract

We have investigated the development of murine hindlimb ischemia from day 1 to day 55 after femoral artery ligation (FAL) using blood flow analysis, functional tests, histopathological staining, and in vivo Raman spectroscopy. FAL resulted in hindlimb blood deprivation and the loss of functionality as attested by the blood flow analysis and functional tests, respectively. The limbs recovered a normal circulation progressively without recovering complete functionality. Histological analysis showed changes in the morphology of muscle fibers with intense inflammation. From day 22 to day 55 post-ischemia, regeneration of the myofibers was observed. Raman spectroscopic results related to subcutaneous analysis made the identification of modification in the biochemical constituents of hindlimb muscles possible during disease progression. Ischemia was characterized by a quantitative increase in the lipid content and a decrease in the protein content. The lipid to protein ratio can be used as a spectroscopic marker to score the severity of ischemia. Multivariate statistical analysis PC-LDA (Principal Component-Linear Discriminant Analysis) was used to classify all the data measured for the normal and ischemic tissues. This classification illustrated an excellent separation between the control and ischemic tissues at any time during the course of ischemic development. In vivo Raman spectroscopy was then applied to assess the potential of this technique as a screening tool to explore an ischemic disease non-invasively (transcutaneously). For this purpose, the influence of skin on the diagnostic accuracy was evaluated; transcutaneous analysis revealed the accuracy of this technique, indicating its potential in the in situ monitoring of muscle structural changes during ischemia.

Related Literature

Front cover

Other

DOI: 10.1039/NP98805FX009

Courses

Other

DOI: 10.1039/JA989040244A

Front cover

Other

DOI: 10.1039/NP99512FX026

David John Faulkner. 10th June 1942–23rd November 2002

2004-02-05 Editorial

DOI: 10.1039/B401803F

Contents pages

Other

DOI: 10.1039/JA98803BX007

Hot off the press

2000-07-05 Paper

DOI: 10.1039/B004632I

Atomic Spectrometry Update References

Paper

DOI: 10.1039/JA988030187R

Hot off the press

2001-05-09 Hot off the Press Article

DOI: 10.1039/B103347F

You might also like

Compound Q&A

How should waste containing (6-Bromo-2-naphthyl)oxy](dimethyl)(2-methyl-2-propanyl)silane be handled?

Waste containing (6-Bromo-2-naphthyl)oxy](dimethyl)(2-methyl-2-propanyl)silane (...

100751-65-3[(6-Bromo-2-naphthyl...
Compound Q&A

How is 7-Fluoro-4-isoquinolinecarboxylic acid (CAS: 1841081-40-0) typically synthesized?

7-Fluoro-4-isoquinolinecarboxylic acid can be synthesized via a multi-step proce...

1841081-40-07-Fluoro-4-isoquinol...
Compound Q&A

What are the physical and chemical properties of 2,3,5,6-Tetrabromothieno[3,2-b]thiophene (CAS: 124638-53-5)?

2,3,5,6-Tetrabromothieno[3,2-b]thiophene is a crystalline compound with a high m...

124638-53-52,3,5,6-Tetrabromoth...
Compound Q&A

Is 1-[4-(Benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide (CAS: 1542705-92-9) safe?

1-[4-(Benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indol...

1542705-92-91-[4-(Benzylamino)-7...
Compound Q&A

What is the market or research trend for imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid, 3,4-dihydro-3-methyl-4-oxo- (CAS: 113942-30-6)?

The market for imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid, 3,4-dihydro-3...

113942-30-6Imidazo[5,1-d]-1,2,3...
Compound Q&A

What is 3-(Triisopropylsilyl)propiolaldehyde (CAS: 163271-80-5)?

3-(Triisopropylsilyl)propiolaldehyde is a synthetic organic compound with the CA...

163271-80-53-(Triisopropylsilyl...
Compound Q&A

What regulatory guidelines apply to 6-Nitro-2H-1,4-benzoxazin-3(4H)-one (CAS: 81721-87-1)?

6-Nitro-2H-1,4-benzoxazin-3(4H)-one (CAS: 81721-87-1) is subject to various regu...

81721-87-16-Nitro-2H-1,4-benzo...
Compound Q&A

How should waste containing (3-Fluorophenyl)(4-{[(2-methyl-2-propanyl)oxy]carbonyl}-1-piperazinyl)acetic acid (CAS: 885272-91-3) be handled?

Waste containing (3-Fluorophenyl)(4-{[(2-methyl-2-propanyl)oxy]carbonyl}-1-piper...

885272-91-3(3-Fluorophenyl)(4-{...
Compound Q&A

What are the physical and chemical properties of N,N'-4,4'-Biphenyldiyldiisonicotinamide (CAS: 55119-40-9)?

N,N'-4,4'-Biphenyldiyldiisonicotinamide is a white crystalline solid with a mole...

55119-40-9N,N'-4,4'-Biphenyldi...
Compound Q&A

What industries use 6-Bromo-8-fluoro-2-quinazolinol (CAS: 1036756-15-6)?

6-Bromo-8-fluoro-2-quinazolinol is primarily used in the pharmaceutical industry...

1036756-15-66-Bromo-8-fluoro-2-q...

Source Journal

Analyst

Analyst
CiteScore: 7.8
Self-citation Rate: 5.6%
Articles per Year: 653

Analyst publishes analytical and bioanalytical research that reports premier fundamental discoveries and inventions, and the applications of those discoveries, unconfined by traditional discipline barriers.

Recommended Compounds

Recommended Suppliers

Disclaimer
This page provides academic journal information for reference and research purposes only. We are not affiliated with any journal publishers and do not handle publication submissions. For publication-related inquiries, please contact the respective journal publishers directly.
If you notice any inaccuracies in the information displayed, please contact us at support@chemtradehub.com. We will promptly review and address your concerns.